A systematic evaluate of VIP in experimental autoimmune encephalomyelitis (the MS product) located that VIP administration lowered clinical severity scores by 40–sixty five% throughout 12 independent experiments, with histological Assessment showing decreased CNS infiltration of Th1 and Th17 cells and increased Foxp3+ Tregs during the spinal twin